Quick Answer
IMPACT BIOMEDICAL INC. reported R&D Expense of $340.0 thousand for fiscal year 2025.
IMPACT BIOMEDICAL INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $340.0K | +22.3% |
| 2024 | $278.0K | -83.5% |
| 2023 | $1.69M | +37.4% |
| 2022 | $1.23M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $52.0K | -36.6% | -30.7% |
| June 30, 2025 | $75.0K | -38.0% | -27.2% |
| March 31, 2025 | $103.0K | -43.7% | +25.6% |
| September 30, 2024 | $82.0K | -77.0% | -32.2% |
| June 30, 2024 | $121.0K | -54.5% | -33.9% |
| March 31, 2024 | $183.0K | +2.2% | -48.7% |
| September 30, 2023 | $357.0K | +8.2% | +34.2% |
| June 30, 2023 | $266.0K | +29.1% | +48.6% |
- IMPACT BIOMEDICAL INC. showed an increase of +22.3% in R&D Expense compared to the prior fiscal year.
- Over the 2022–2025 period, IMPACT BIOMEDICAL INC.’s r&d expense has declined by 72.3% (from $1.23 million to $340.0 thousand).
- The most recent figure is from IMPACT BIOMEDICAL INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 11, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: